TiA1 in advanced-stage classical Hodgkin’s lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells

详细信息    查看全文

• 作者：Sophie Camilleri-Bro?t ; Christophe Fermé ; Fran?oise Berger ; Eric Lepage ; Serge Bain ; Josette Brière ; Béatrice Marmey ; Philippe Gaulard and Josée Audouin
• 关键词：Immunohistochemistry ; Lymphoma ; Clinical pathology
• 刊名：Virchows Archiv
• 出版年：2004
• 出版时间：October 2004
• 年：2004
• 卷：445
• 期：4
• 页码：344-346
• 全文大小：177 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2307

文摘

No reliable marker still exists for predicting those patients with Hodgkins lymphoma (HL) who may experience a fatal outcome. Among the factors tested in the literature, it has been suggested that the number of activated cytotoxic T cells may represent a prognostic marker in HL. In 244 samples from patients with stage-IIIB/IV HL issued from the GELA H89 trial, we have analysed TiA1 expression on Reed Sternberg (RS) cells as well as the percentage of positive reactive lymphocytes. There were 34 cases (13.7%) that showed TiA1 expression on tumour cells; whereas, in 32 cases (13.1%), TiA1-positive reactive lymphocytes represented more than 30% of the reactive lymphocytes. LMP-1 was found co-expressed with TiA1 in 10 of the 22 positive cases tested. Our study confirms that a subset of classical HL expresses cytotoxic proteins, with occasional co-expression of CD20. In stage-IIIB/IV disease, neither TiA1 expression by RS cells nor a high percentage of TiA1-positive reactive lymphocytes have a prognostic impact on outcome.